United Therapeutics Corporation $UTHR Shares Purchased by MPM Bioimpact LLC

Key Points

• MPM Bioimpact LLC increased its stake in United Therapeutics by 156.1% in Q1, owning approximately $18.2 million worth of shares.
• Analysts have given United Therapeutics an average rating of Moderate Buy with a target price of $382.00, though estimates vary with some as high as $415.00.
• Insider sales included EVP Paul A. Mahon selling 11,000 shares for approximately $3.4 million, representing a significant decrease in his ownership by 23.02%.

MPM Bioimpact LLC raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 156.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,907 shares of the biotechnology company's stock after purchasing an additional 35,907 shares during the period. United Therapeutics accounts for 3.1% of MPM Bioimpact LLC's portfolio, making the stock its 12th largest position. MPM Bioimpact LLC owned about 0.13% of United Therapeutics worth $18,159,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in shares of United Therapeutics in the first quarter worth $313,000. Allianz Asset Management GmbH increased its position in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after acquiring an additional 33,254 shares in the last quarter. LPL Financial LLC increased its position in shares of United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after acquiring an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 376 shares in the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of United Therapeutics in the first quarter worth $227,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several analyst reports. HC Wainwright set a $400.00 target price on shares of United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. UBS Group upped their target price on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Bank of America decreased their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $382.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director directly owned 4,883 shares in the company, valued at $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,681 shares of company stock valued at $24,537,839 over the last three months. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $304.76 on Tuesday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The company has a market capitalization of $13.75 billion, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 4.62 and a beta of 0.62. The company's fifty day moving average price is $299.03 and its two-hundred day moving average price is $304.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period last year, the company posted $5.85 earnings per share. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.